NCT07337174

Brief Summary

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_1 obesity

Timeline
Completed

Started Jan 2026

Shorter than P25 for phase_1 obesity

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 22, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

January 13, 2026

Completed
12 days until next milestone

Study Start

First participant enrolled

January 25, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 24, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 24, 2026

Completed
Last Updated

January 13, 2026

Status Verified

December 1, 2025

Enrollment Period

2 months

First QC Date

December 22, 2025

Last Update Submit

January 6, 2026

Conditions

Obesity

Outcome Measures

Primary Outcomes (2)

  • Cmax following single-dose administration

    0 through 72 hours post-dose

  • AUC following single-dose administration

    0 through 72 hours post-dose

Study Arms (2)

HUC2-676

EXPERIMENTAL
Drug: HUC2-676

HUC2-676-R

ACTIVE COMPARATOR
Drug: HUC2-676-R

Interventions

HUC2-676DRUG

subcutaneous injection

HUC2-676
HUC2-676-RDRUG

subcutaneous injection

HUC2-676-R

Eligibility Criteria

Age19 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy adult volunteers aged 19 to 65 years, inclusive, at screening.
  • Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.

You may not qualify if:

  • Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders.
  • For females: Pregnant women (positive urine hCG) or nursing mothers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Park

    Chungbuk National University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Huons

CONTACT

82-070-7492-6091rlee@huons.com

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 22, 2025

First Posted

January 13, 2026

Study Start

January 25, 2026

Primary Completion

March 24, 2026

Study Completion

March 24, 2026

Last Updated

January 13, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share